Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Paul Hartmann AG

Start price
Target price
Perf. (%)
€353.00
30.06.21
€400.00
30.06.22
3.40%
10.07.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
buy
Ocuphire Pharma Inc.

Start price
Target price
Perf. (%)
€5.00
30.06.21
€8.00
30.06.22
-22.40%
09.07.21

Could be worthwhile Investment >10% per year
Good culture
Little innovation
Abivax S.A.

Start price
Target price
Perf. (%)
€30.50
28.06.21
€25.00
28.06.22
-16.39%
01.12.21

Future proof or reliable business model
Probably not worthwhile Investment
overvalued
Very low/no dividend yield expected
buy
Syros Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€46.00
26.06.21
-
26.06.22
-81.82%
27.06.22

Could be very worthwhile Investment >20% year
Osmotica Pharmaceuticals PLC

Start price
Target price
Perf. (%)
€3.04
26.06.21
€1.00
26.06.22
-18.42%
10.07.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€16.08
24.06.21
€4.80
24.06.22
-60.12%
20.12.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€11.37
17.06.21
€18.00
09.03.22
95.60%
10.03.22

Could be very worthwhile Investment >20% year
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€53.25
17.06.21
-
09.03.22
-
17.06.21

Could be very worthwhile Investment >20% year
buy
co.don AG

Start price
Target price
Perf. (%)
€1.41
17.06.21
-
17.06.23
-13.17%
17.06.23

Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Could be very worthwhile Investment >20% year
Valneva SE

Start price
Target price
Perf. (%)
€10.89
17.06.21
€8.00
17.06.22
3.21%
20.07.21

Could be worthwhile Investment >10% per year
Very valuable balance sheet
Avid Bioservices Inc

Start price
Target price
Perf. (%)
€20.60
17.06.21
€17.00
17.06.22
38.84%
26.11.21

Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.

Start price
Target price
Perf. (%)
€73.80
17.06.21
€50.00
17.06.22
-66.50%
17.08.21

Could be worthwhile Investment >10% per year
buy
ShockWave Medical Inc

Start price
Target price
Perf. (%)
€159.00
16.06.21
€225.00
16.06.22
-5.66%
16.06.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Novan Inc

Start price
Target price
Perf. (%)
€15.74
14.06.21
-
14.06.22
-40.72%
17.06.21

Risky Investment
buy
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€13.20
14.06.21
€24.00
14.06.22
0.00%
26.06.21

Could be worthwhile Investment >10% per year
Good culture
Little innovation
buy
Avid Bioservices Inc

Start price
Target price
Perf. (%)
€19.30
14.06.21
€22.00
14.06.22
6.74%
17.06.21

Could be worthwhile Investment >10% per year
buy
CareCloud Inc.

Start price
Target price
Perf. (%)
€7.30
12.06.21
€8.50
12.06.22
-6.16%
10.07.21

Growths slower than the competition
Below average Marketposition
Revenue decline/stagnation expected
EBIT decline/stagnation expected
buy
CareCloud Inc.

Start price
Target price
Perf. (%)
€7.30
12.06.21
-
12.06.22
-55.62%
12.06.22

buy
Novan Inc

Start price
Target price
Perf. (%)
€12.12
12.06.21
-
12.06.22
-81.58%
13.06.22

Could be worthwhile Investment >10% per year
buy
Aptose Biosciences

Start price
Target price
Perf. (%)
€3.22
11.06.21
€4.00
11.06.22
-69.57%
14.12.21

Could be worthwhile Investment >10% per year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€18.77
11.06.21
€23.20
11.06.22
-14.32%
24.06.21

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
M1 Kliniken AG

Start price
Target price
Perf. (%)
€10.35
31.05.21
-
31.05.24
40.10%
11.03.24

Could be worthwhile Investment >10% per year
buy
Haemato AG

Start price
Target price
Perf. (%)
€29.20
31.05.21
-
31.05.24
-36.99%
11.03.24

Could be worthwhile Investment >10% per year
buy
Sangamo Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.74
31.05.21
€15.00
31.05.22
-60.61%
01.06.22

Fair valuation
Strong uniques
Leading role in innovation
Bad rating
buy
Corvus Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€2.18
31.05.21
€4.00
31.05.22
4.59%
14.06.21

Could be worthwhile Investment >10% per year